The invention discloses a method for encapsulated osteoblasts to support and regulate the in-vitro amplification of
cord blood hematopoieticstem / progenitorcells (He) in the hypoxia condition, belonging to the fields of
biotechnology and tissue TSPCS
engineering. The method is characterized in that the human osteoblasts are embedded by
gelatin-alginate-
chitosan (GAC) microcapsule as matrix feeder cells and co-cultured with the
cord blood HSPCs in the 5% hypoxia environment to obtain the HSPCs. The invention adopts GAC microcapsule to separate the human osteoblasts from the
cord blood HSPCs to avoid the
cell contamination and immunological rejection. Furthermore, the pore passages of the microcapsule are capable of causing hemopoietic growth factors secreted by the osteoblasts in the microcapsule to expand to the
habitat of the HSPCs and play a role of stimulating the amplification of the hematopoietic stem /
progenitor cells. Moreover, the material of the microcapsule has the slow release function to the expansion of the growth factors to increase the
concentration gradient of the growth factors on the surface of the microcapsule, which is helpful for the long-term function of the
growth factor. In addition, the microencapsulated osteoblasts form the 3D environment, which not only causes the culture
system to contain more osteoblasts, but also causes the culture
system to have bigger HSPCs-OBs action area compared with the co-culture pattern of the osteoblasts cultured by adherence. Besides, in the 5% hypoxia environment, the co-culture
system is capable of better simulating the hematopoietic microenvironment iche of
human bone marrow the osteoblasts have significant effects on the characteristic maintenance and number amplification of stem cells of the HSPCs.